Translational research in the pharmaceutical industry: from theory to reality

Drug Discovery Today

Volumn 12, Issue 9-10, 2007, Pages 419-425

  Sultana, Stefan R ^a   Roblin, David ^a   O'Connell, Damian ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1A ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN II; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; ATRIAL NATRIURETIC FACTOR; BRADYKININ; BRAIN NATRIURETIC PEPTIDE; CANDOXATRIL; CANDOXATRILAT; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CISAPRIDE; CYCLIC GMP; ENDOTHELIN 1; ENKEPHALIN DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MARAVIROC; PHOSPHODIESTERASE V INHIBITOR; SEROTONIN; SEROTONIN 4 AGONIST; SEROTONIN 4 RECEPTOR; SILDENAFIL; TRASTUZUMAB; UK 338003; UNCLASSIFIED DRUG; VARDENAFIL;

ADENOHYPOPHYSIS; BLOOD OXYGENATION; BREAST CANCER; CENTRAL NERVOUS SYSTEM; CONGESTIVE HEART FAILURE; CORPUS CAVERNOSUM; DOSE RESPONSE; DRUG INDUSTRY; DRUG RESEARCH; DRUG TARGETING; ELECTROENCEPHALOGRAM; ERECTILE DYSFUNCTION; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GASTROESOPHAGEAL REFLUX; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENOME ANALYSIS; HIGH SODIUM INTAKE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; MAXIMUM TOLERATED DOSE; MEDICAL RESEARCH; NONHUMAN; PHARMACOGENOMICS; POSITRON EMISSION TOMOGRAPHY; PROSTATE HYPERTROPHY; PULMONARY HYPERTENSION; REVIEW; RNA TRANSLATION; SINGLE NUCLEOTIDE POLYMORPHISM; THEORETICAL STUDY;

ANIMALS; DRUG DESIGN; DRUG INDUSTRY; DRUG THERAPY; EFFICIENCY, ORGANIZATIONAL; HUMANS; TECHNOLOGY TRANSFER;

EID: 34247387591     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2007.03.009     Document Type: Review

References (52)

1. O'Connell D., and Roblin D. Translational research in the pharmaceutical industry: from bench to bedside. Drug Discov. Today 11 (2006) 833-838
2. Hirata Y., et al. Mechanisms of the natriuretic effects of neutral endopeptidase inhibition in Dahl salt-sensitive and salt-resistant rats. J. Cardiovasc. Pharmacol. 23 (1994) 283-290
3. Northridge D.B., et al. Effect of UK-69578: a novel atriopeptidase inhibitor. Lancet 2 (1989) 591-593
4. O'Connell J.E. Renal and hormonal effects of chronic inhibition of neutral endopeptidase (EC 3.4.24.11) in normal man. Clin. Sci. 85 (1993) 19-26
5. Kimmelstiel C.D., et al. Effects of renal neutral endopeptidase on sodium excretion, renal hemodynamics and neurohormonal activation in patients with congestive heart failure. Cardiology 87 (1996) 46-53
6. Sagnella G.A., et al. Hormonal and renal responses to neutral endopeptidase inhibition in normal humans on a low and on a high sodium intake. Eur. J. Clin. Invest. 25 (1995) 165-170
7. Lefebvre H., et al. The serotonin-4 receptor agonist cisapride and angiotensin-II exert additive effects on aldosterone secretion in normal man. J. Clin. Endocrinol. Metab. 80 (1995) 504-507
8. Lefebvre H., et al. Effect of prolonged administration of the serotonin4 (5-HT4) receptor agonist cisapride on aldosterone secretion in healthy volunteers. Endocr. Res. 24 (1998) 749-752
9. Gale J.D., et al. The effect of repeat dosing of mosapride on plasma aldosterone in healthy Japanese volunteers. Br. J. Clin. Pharmacol. 59 (2005) 637 (abstract)
10. Samuels E.R., et al. Comparison of pramipexole and amisulpride on alertness, autonomic and endocrine functions in healthy volunteers. Psychopharmacology 187 (2006) 498-510
11. Rihet P., et al. Dopamine and human information processing: a reaction-time analysis of the effect of levodopa in healthy subjects. Psychopharmacology 163 (2002) 62-67
12. Preece M., et al. Detection of pharmacologically mediated changes in cerebral activity by functional magnetic resonance imaging: the effects of sulpiride in the brain of the anaesthetised rat. Brain Res. 916 (2001) 107-114
13. Takahashi H., et al. Effects of dopaminergic and serotonergic manipulation on emotional processing: a pharmacological fMRI study. Neuroimage 27 (2005) 991-1001
14. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA 270 (1993) 83-90
15. Boolell M., et al. Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br. J. Urol. 78 (1996) 257-261
16. Diamond L.E., et al. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int. J. Impot. Res. 16 (2004) 51-59
17. Hedlund P. PT-141 Palatin. Curr. Opin. Investig. Drugs 5 (2004) 456-462
18. Pryor J. Vardenafil: update on clinical experience. Int. J. Impot. Res. 14 (2002) S65-S69
19. Carter A.J., et al. Effect of the selective phosphodiesterase type 5 inhibitor sildenafil on erectile dysfunction in the anesthetized dog. J. Urol. 160 (1998) 242-246
20. Hosogai N., et al. FR226807: a potent and selective phosphodiesterase type 5 inhibitor. Eur. J. Pharmacol. 428 (2001) 295-302
21. Qiu Y., et al. Characterization of a novel phosphodiesterase type 5 inhibitor: JNJ-10258859. Eur. J. Pharmacol. 472 (2003) 73-80
22. Kenny B.A., et al. Effect of alpha 1 adrenoceptor antagonists on prostatic pressure and blood pressure in the anesthetized dog. Urology 44 (1994) 52-57
23. Sultana S.R., et al. Alpha-adrenoceptor antagonist selectivity determined by simultaneous blood pressure and long-term urethral pressure monitoring in men. Br. J. Clin. Pharmacol. 45 (1998) 192 (abstract)
24. Sultana S.R., et al. Experiences with dose finding in patients in early drug development: the use of biomarkers in early decision making. In: Venitz J., and Sittner W. (Eds). Appropriate Dose Selection: How to Optimise Clinical Drug Development; Ernst Schering Res. Found. Workshop (59) (2007), Springer 65-79
25. Cocchi F., et al. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 270 (1995) 1811-1815
26. Paxton W.A., et al. Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure. Nat. Med. 2 (1996) 412-417
27. Connor R.I., et al. Macrophages and CD4+ T lymphocytes from two multiply exposed, uninfected individuals resist infection with primary non-syncytium-inducing isolates of human immunodeficiency virus type 1. J. Virol. 70 (1996) 8758-8764
28. Liu R., et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86 (1996) 367-377
29. Samson M., et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382 (1996) 722-725
30. Dean M., et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 273 (1996) 1856-1862
31. Eugen-Olsen J., et al. Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals. AIDS 11 (1997) 305-310
32. Dorr P., et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49 (2005) 4721-4732
33. Fätkenheuer G., et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist in HIV-1-infected patients. Nat. Med. 2005 (2005) 1170-1172
34. Mank-Seymour A.R., et al. Association between single-nucleotide polymorphisms in the endothelial lipase (LIPG) gene and high-density lipoprotein cholesterol levels. Biochim. Biophys. Acta 1636 (2004) 40-46
35. Ishida T., et al. Endothelial lipase is a major determinant of HDL level. J. Clin. Invest. 11 (2003) 347-355
36. deLemos A.S., et al. Identification of genetic variants in endothelial lipase in persons with elevated high-density lipoprotein cholesterol. Circulation 106 (2002) 1321-1326
37. Ma K., et al. Endothelial lipase is a major genetic determinant for high-density lipoprotein concentration, structure, and metabolism. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 2748-2753
38. Gretarsdottir S., et al. The gene encoding phosphodiesterase 4D confers risk of ischemic stroke. Nat. Genet. 35 (2005) 131-138 Erratum in. Nat. Genet. 37, 555
39. Stefansson H., et al. Neuregulin 1 and susceptibility to schizophrenia. Am. J. Hum. Genet. 71 (2002) 877-892
40. Ogura Y., et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411 (2001) 603-606
41. Helgadottir A., et al. The gene encoding 5-lipoxygenase-activating protein confers risk of myocardial infarction and stroke. Nat. Genet. 36 (2004) 233-239
42. Helgadottir A., et al. A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat. Genet. 38 (2006) 68-74
43. Slamon D.J., et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
44. Shepard H.M., et al. Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J. Clin. Immunol. 11 (1991) 117-127
45. Cobleigh M.A., et al. Multinational study of the efficacy and safety of humanized Anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17 (1991) 2639-2648
46. Ghofrani H.A., et al. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat. Rev. Drug Discov. 2006 (2006) 689-702
47. Jackson G., et al. Past, present, and future: a 7-year update of Viagra (sildenafil citrate). Int. J. Clin. Pract. 59 (2005) 680-691
48. Gillies H.C., et al. Coronary and systemic hemodynamic effects of sildenafil citrate: from basic science to clinical studies in patients with cardiovascular disease. Int. J. Cardiol. 86 (2002) 131-141
49. Ladha F., et al. Sildenafil improves alveolar growth and pulmonary hypertension in hyperoxia-induced lung injury. Am. J. Respir. Crit. Care Med. 172 (2005) 750-756
50. Wilkens H., et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 104 (2001) 1218-1222
51. Lee A.J., et al. Sildenafil for pulmonary hypertension. Ann. Pharmacother. 39 (2005) 869-884
52. Rosen R.C., et al. The international index of erectile dysfunction (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 49 (1997) 822-830